Pipeline

DEVELOPMENT STAGE & ANTICIPATED MILESTONES THERAPEUTIC INDICATION ANTIBODY PROGRAM LEAD OPTIMIZATION IND-ENABLING PHASE 1 PHASE 2 PHASE 3 ANB032: Anti-BTLA Agonist Inflammatory Diseases Phase 1 Top-LineData AnouncedApril 2022 IND Filing of Phase 2 Trialin Q4 2022 Rosnilimab (ANB030):Anti-PD-1 Agonist Alopecia Areata Phase 1 Top-LineData AnouncedNov 2021 AZURE: Top-Line Data Anticipated Q1 2023 Imsidolimab (ANB019):Anti-IL-36R Generalized PustularPsoriasis Phase 1 DataPresented atEAACI 2018 ANB033: Antagonist mAb Inflammatory Diseases Phase 1 Top-LineData AnouncedApril 2022 IND Filing H1 2024 GALLOP: Phase 2 Data Presented AtEADV Congress on October 2nd 2021 Top-Line DataAnticipated Q4 2023